TY - JOUR T1 - <sup>18</sup>F-FDG PET/CT Identifies Predictors of Survival in Patients with Locally Advanced Cervical Carcinoma and Paraaortic Lymph Node Involvement to Allow Intensification of Treatment JF - Journal of Nuclear Medicine JO - J Nucl Med SP - 1442 LP - 1447 DO - 10.2967/jnumed.119.238824 VL - 61 IS - 10 AU - Hélène Leray AU - Erwan Gabiache AU - Frédéric Courbon AU - Isabelle Brenot-Rossi AU - Hélène Colineaux AU - Benoît Lepage AU - Eric Lambaudie AU - Alejandra Martinez AU - Marie Voglimacci AU - Ariane Weyl AU - Marion Deslandres AU - Anne Ducassou AU - Stéphanie Motton AU - Charlotte Vaysse AU - Elodie Chantalat Y1 - 2020/10/01 UR - http://jnm.snmjournals.org/content/61/10/1442.abstract N2 - Our objective was to use 18F-FDG PET/CT to identify a high-risk subgroup requiring therapeutic intensification among patients with locally advanced cervical cancer (LACC) and paraaortic lymph node (PALN) involvement. Methods: In this retrospective multicentric study, patients with LACC and PALN involvement concurrently treated with chemoradiotherapy and extended-field radiotherapy between 2006 and 2016 were included. A senior nuclear medicine specialist in PET for gynecologic oncology reviewed all 18F-FDG PET/CT scans. Metabolic parameters including SUVmax, metabolic tumor volume, and total lesion glycolysis (TLG) were determined for the primary tumor, pelvic lymph nodes, and PALNs. Associations between these parameters and overall survival (OS) were assessed with the Cox proportional hazards model. Results: Sixty-eight patients were enrolled in the study. Three-year OS was 55.5% (95% confidence interval, 40.8–68.0). When adjusted for age, stage, and histology, pelvic lymph node TLG, PALN TLG, and PALN SUVmax were significantly associated with OS (P &lt; 0.005). Conclusion: 18F-FDG PET/CT was able to identify predictors of survival in the homogeneous subgroup of patients with LACC and PALN involvement, thus allowing therapeutic intensification to be proposed. ER -